SlideShare a Scribd company logo
Lung Cancer
1
Men
Lung and bronchus 28%
Prostate 11%
Colon and rectum 8%
Pancreas 6%
Leukemia 4%
Women
Lung and bronchus 26%
Breast 15%
Colon and rectum 9%
Pancreas 7%
Ovary 6%
American Cancer Society. Cancer Facts & Figures 2011.
NSCLC
85%
Lung cancer subtypes
Squamous cell carcinoma 25%
Small-cell carcinoma 15%
Large-cell carcinoma 10%
Adenocarcinoma 45%
• Leading cause of cancer-related deaths
• Non-small cell lung cancer (NSCLC) is the most common form
LKB1 and Metabolism
2
Front. Oncol., 14 July 2013 | doi: 10.3389/fonc.2013.00175.
Targets of LKB1 Kinase
3
• Cell polarity
• Proliferation
• CREB related gene
transcription
Knockdown of DTYMK in LKB1-WT and LKB1-
mutant NSCLC cell lines.
Liu Y et al. Cancer Discovery 2013;3:870-879
B
Aims
5
To investigate the effect of sensitivity of non-small cell
lung cancer cells expressing wild-type or mutant LKB1 to
inhibitors of CHK1/2 and NUAK1
Cell lines:
A549 (Human alveolar
adenocarcinoma cell line):
• A549LKB1- Intact LKB1
• A549 BABE- knockout LKB1
Compounds:
AZD7762 (CHK1/2 inhibitor])
WZ4002 (NUAK1 inhibitor)
What did we do?
 Resazurin proliferation assay
- 1000 cells in 96 well plate; add dilution of drug, incubate 3 days, add resazurin, resazurin taken
up by living cells and reduced to fluorescent Resorufin
 Western Blot
- Check for LKB1 presence/absence
 FACS analysis
- Determine proportion of cells in G1 phase, high proportion suggests slow growth rate
 PicoGreen proliferation assay
- 1000 cells into 96 well plate, for each day, remove cell medium, add lysis buffer, this fixes the
number of cells present on that day. PicoGreen dye + OMEGA plate reader.
Resazurin proliferation assay
7
Western Blot
8
Western Blot
9
FACS analysis
10
Phase %G1 %S %G2 COUNT
BABE
control
52.8 22.7 21.8 8795
BABE
AZD
63.6 16.9 18.3 8991
BABE
WZ
55.4 19.8 20 8933
LKB1
control
62.1 11.7 16.4 9206
LKB1
AZD
63.1 28.5 0 7862
LKB1 WZ 59.4 16.8 17 8835
FACS Analysis
11
PicoGreen assay
12
• The A549-LKB appeared to grow more rapidly
• The reduced DNA content on day 3 likely represents cells dying or becoming confluent
• AZD7762 has little effect in either cell line
• WZ4002 had a modest growth inhibitory effect in both cell lines
Fluorescence
Fluorescence
Days Days
Summary of results
13
1. LKB1 expression does not affect sensitivity to AZD7762 but increases sensitivity to
WZ4002 (slightly)
2. PARP levels lower in cells expressing LKB1, but uncertain relevance
3. Higher % of cells in G1 in LKB1 expressing cells
4. LKB1 expressing cells grew faster, but not differentially sensitive to AZD or WZ
5. Similar data in another cell line (A427)
6. More work needed to better understand results

More Related Content

Viewers also liked

Leprosy - Dr. Julius King Kwedhi
Leprosy - Dr. Julius King KwedhiLeprosy - Dr. Julius King Kwedhi
Leprosy - Dr. Julius King Kwedhi
Dr. Julius Kwedhi
 
Bronchogenic carcinoma
Bronchogenic carcinomaBronchogenic carcinoma
Bronchogenic carcinoma
Foyez Ahmed Hasan
 
Chest X Rays
Chest X RaysChest X Rays
Chest X Rays
Suneet Khurana
 
Pathophysiology of Leprosy
Pathophysiology of LeprosyPathophysiology of Leprosy
Pathophysiology of Leprosy
Urmila Aswar
 
Leprosy for undergraduate medical students
Leprosy for undergraduate medical studentsLeprosy for undergraduate medical students
Leprosy for undergraduate medical students
Ali Gargoom
 
Eye in leprosy
Eye in leprosyEye in leprosy
Eye in leprosy
Dr Anand
 
Typhoid fever ppt
Typhoid fever pptTyphoid fever ppt
Typhoid fever pptAnwar Ahmad
 

Viewers also liked (10)

Leprosy - Dr. Julius King Kwedhi
Leprosy - Dr. Julius King KwedhiLeprosy - Dr. Julius King Kwedhi
Leprosy - Dr. Julius King Kwedhi
 
Bronchogenic carcinoma
Bronchogenic carcinomaBronchogenic carcinoma
Bronchogenic carcinoma
 
Chest X Rays
Chest X RaysChest X Rays
Chest X Rays
 
Pathophysiology of Leprosy
Pathophysiology of LeprosyPathophysiology of Leprosy
Pathophysiology of Leprosy
 
Leprosy for undergraduate medical students
Leprosy for undergraduate medical studentsLeprosy for undergraduate medical students
Leprosy for undergraduate medical students
 
Eye in leprosy
Eye in leprosyEye in leprosy
Eye in leprosy
 
Leprosy
LeprosyLeprosy
Leprosy
 
Leprosy
LeprosyLeprosy
Leprosy
 
6 lungcancer
6 lungcancer6 lungcancer
6 lungcancer
 
Typhoid fever ppt
Typhoid fever pptTyphoid fever ppt
Typhoid fever ppt
 

Similar to LKB1

article
articlearticle
article
dalya shakir
 
Crizotinib a8081001 asco 2010 slides
Crizotinib a8081001 asco 2010 slides Crizotinib a8081001 asco 2010 slides
Crizotinib a8081001 asco 2010 slides
coolesanum
 
Treatment of High Risk Myelofibrosis.
Treatment of High Risk Myelofibrosis.Treatment of High Risk Myelofibrosis.
Treatment of High Risk Myelofibrosis.
spa718
 
Genetic susceptibility to leukemia
Genetic susceptibility to leukemiaGenetic susceptibility to leukemia
Genetic susceptibility to leukemia
Dr. Ankit Jitani
 
ALK INHIBITORS NSCLC.pptx
ALK INHIBITORS NSCLC.pptxALK INHIBITORS NSCLC.pptx
ALK INHIBITORS NSCLC.pptx
Seraj Aldeen
 
Evolocumab HCP presentation.pptx
Evolocumab HCP presentation.pptxEvolocumab HCP presentation.pptx
Evolocumab HCP presentation.pptx
AdelSALLAM4
 
1.2.6_NOTCH_signaling_pathway._corrected[1].pptx
1.2.6_NOTCH_signaling_pathway._corrected[1].pptx1.2.6_NOTCH_signaling_pathway._corrected[1].pptx
1.2.6_NOTCH_signaling_pathway._corrected[1].pptx
ByamugishaJames
 
Molecules in lung cancer part 2
Molecules in lung cancer part 2Molecules in lung cancer part 2
Molecules in lung cancer part 2
კონსილიუმ მედულა
 
ACUTE MYELOID LEUKEMIA
ACUTE MYELOID LEUKEMIAACUTE MYELOID LEUKEMIA
ACUTE MYELOID LEUKEMIA
flasco_org
 
Integrated haematopathology
Integrated haematopathology Integrated haematopathology
Integrated haematopathology
Dr. Rajesh Bendre
 
Serum Free Light Chains
Serum Free Light ChainsSerum Free Light Chains
Serum Free Light Chains
HOWARD ROBIN
 
Bioinformatic data analysis – comparison from three human studies using diffe...
Bioinformatic data analysis – comparison from three human studies using diffe...Bioinformatic data analysis – comparison from three human studies using diffe...
Bioinformatic data analysis – comparison from three human studies using diffe...
Agnieszka Caruso
 
B cell malignancies and the Kidney
B cell malignancies and the KidneyB cell malignancies and the Kidney
B cell malignancies and the Kidney
kdj200
 
Treatment landscape of alk+ nsclc 12 november
Treatment landscape of alk+ nsclc 12 novemberTreatment landscape of alk+ nsclc 12 november
Treatment landscape of alk+ nsclc 12 november
ssuser4c22ca
 
molecular biology and Target therapy in lung cancer
molecular biology and Target therapy in lung cancermolecular biology and Target therapy in lung cancer
molecular biology and Target therapy in lung cancer
Rikin Hasnani
 
Chemotherapy in Gynecological malignancies
Chemotherapy in Gynecological malignancies Chemotherapy in Gynecological malignancies
Chemotherapy in Gynecological malignancies
Chandan K Das
 
Cell cycle regulation
Cell cycle regulationCell cycle regulation
Cell cycle regulation
Creative-Bioarray
 
Cell cycle regulation
Cell cycle regulationCell cycle regulation
Cell cycle regulation
Creative-Bioarray
 

Similar to LKB1 (20)

article
articlearticle
article
 
Crizotinib a8081001 asco 2010 slides
Crizotinib a8081001 asco 2010 slides Crizotinib a8081001 asco 2010 slides
Crizotinib a8081001 asco 2010 slides
 
Treatment of High Risk Myelofibrosis.
Treatment of High Risk Myelofibrosis.Treatment of High Risk Myelofibrosis.
Treatment of High Risk Myelofibrosis.
 
Genetic susceptibility to leukemia
Genetic susceptibility to leukemiaGenetic susceptibility to leukemia
Genetic susceptibility to leukemia
 
ALK INHIBITORS NSCLC.pptx
ALK INHIBITORS NSCLC.pptxALK INHIBITORS NSCLC.pptx
ALK INHIBITORS NSCLC.pptx
 
Evolocumab HCP presentation.pptx
Evolocumab HCP presentation.pptxEvolocumab HCP presentation.pptx
Evolocumab HCP presentation.pptx
 
1.2.6_NOTCH_signaling_pathway._corrected[1].pptx
1.2.6_NOTCH_signaling_pathway._corrected[1].pptx1.2.6_NOTCH_signaling_pathway._corrected[1].pptx
1.2.6_NOTCH_signaling_pathway._corrected[1].pptx
 
Acute Lymphoblastic Leukaemia
Acute Lymphoblastic LeukaemiaAcute Lymphoblastic Leukaemia
Acute Lymphoblastic Leukaemia
 
Molecules in lung cancer part 2
Molecules in lung cancer part 2Molecules in lung cancer part 2
Molecules in lung cancer part 2
 
ACUTE MYELOID LEUKEMIA
ACUTE MYELOID LEUKEMIAACUTE MYELOID LEUKEMIA
ACUTE MYELOID LEUKEMIA
 
Integrated haematopathology
Integrated haematopathology Integrated haematopathology
Integrated haematopathology
 
Serum Free Light Chains
Serum Free Light ChainsSerum Free Light Chains
Serum Free Light Chains
 
Bioinformatic data analysis – comparison from three human studies using diffe...
Bioinformatic data analysis – comparison from three human studies using diffe...Bioinformatic data analysis – comparison from three human studies using diffe...
Bioinformatic data analysis – comparison from three human studies using diffe...
 
B cell malignancies and the Kidney
B cell malignancies and the KidneyB cell malignancies and the Kidney
B cell malignancies and the Kidney
 
PosterPDF
PosterPDFPosterPDF
PosterPDF
 
Treatment landscape of alk+ nsclc 12 november
Treatment landscape of alk+ nsclc 12 novemberTreatment landscape of alk+ nsclc 12 november
Treatment landscape of alk+ nsclc 12 november
 
molecular biology and Target therapy in lung cancer
molecular biology and Target therapy in lung cancermolecular biology and Target therapy in lung cancer
molecular biology and Target therapy in lung cancer
 
Chemotherapy in Gynecological malignancies
Chemotherapy in Gynecological malignancies Chemotherapy in Gynecological malignancies
Chemotherapy in Gynecological malignancies
 
Cell cycle regulation
Cell cycle regulationCell cycle regulation
Cell cycle regulation
 
Cell cycle regulation
Cell cycle regulationCell cycle regulation
Cell cycle regulation
 

LKB1

  • 1. Lung Cancer 1 Men Lung and bronchus 28% Prostate 11% Colon and rectum 8% Pancreas 6% Leukemia 4% Women Lung and bronchus 26% Breast 15% Colon and rectum 9% Pancreas 7% Ovary 6% American Cancer Society. Cancer Facts & Figures 2011. NSCLC 85% Lung cancer subtypes Squamous cell carcinoma 25% Small-cell carcinoma 15% Large-cell carcinoma 10% Adenocarcinoma 45% • Leading cause of cancer-related deaths • Non-small cell lung cancer (NSCLC) is the most common form
  • 2. LKB1 and Metabolism 2 Front. Oncol., 14 July 2013 | doi: 10.3389/fonc.2013.00175.
  • 3. Targets of LKB1 Kinase 3 • Cell polarity • Proliferation • CREB related gene transcription
  • 4. Knockdown of DTYMK in LKB1-WT and LKB1- mutant NSCLC cell lines. Liu Y et al. Cancer Discovery 2013;3:870-879 B
  • 5. Aims 5 To investigate the effect of sensitivity of non-small cell lung cancer cells expressing wild-type or mutant LKB1 to inhibitors of CHK1/2 and NUAK1 Cell lines: A549 (Human alveolar adenocarcinoma cell line): • A549LKB1- Intact LKB1 • A549 BABE- knockout LKB1 Compounds: AZD7762 (CHK1/2 inhibitor]) WZ4002 (NUAK1 inhibitor)
  • 6. What did we do?  Resazurin proliferation assay - 1000 cells in 96 well plate; add dilution of drug, incubate 3 days, add resazurin, resazurin taken up by living cells and reduced to fluorescent Resorufin  Western Blot - Check for LKB1 presence/absence  FACS analysis - Determine proportion of cells in G1 phase, high proportion suggests slow growth rate  PicoGreen proliferation assay - 1000 cells into 96 well plate, for each day, remove cell medium, add lysis buffer, this fixes the number of cells present on that day. PicoGreen dye + OMEGA plate reader.
  • 10. FACS analysis 10 Phase %G1 %S %G2 COUNT BABE control 52.8 22.7 21.8 8795 BABE AZD 63.6 16.9 18.3 8991 BABE WZ 55.4 19.8 20 8933 LKB1 control 62.1 11.7 16.4 9206 LKB1 AZD 63.1 28.5 0 7862 LKB1 WZ 59.4 16.8 17 8835
  • 12. PicoGreen assay 12 • The A549-LKB appeared to grow more rapidly • The reduced DNA content on day 3 likely represents cells dying or becoming confluent • AZD7762 has little effect in either cell line • WZ4002 had a modest growth inhibitory effect in both cell lines Fluorescence Fluorescence Days Days
  • 13. Summary of results 13 1. LKB1 expression does not affect sensitivity to AZD7762 but increases sensitivity to WZ4002 (slightly) 2. PARP levels lower in cells expressing LKB1, but uncertain relevance 3. Higher % of cells in G1 in LKB1 expressing cells 4. LKB1 expressing cells grew faster, but not differentially sensitive to AZD or WZ 5. Similar data in another cell line (A427) 6. More work needed to better understand results

Editor's Notes

  1. LKB1 is an upstream kinase of AMPK AMPK: many metabolic pathways in general, switches off ATP consuming pathways and switched on ATP generating pathways. AMPK activated by depleted ATP. ADP and AMP compete for binding to AMPK so ratios determine activation. Activated by p in activation loop of kinase domain. 4 adenine binding clefts: 1 always unoccupies, 1 always bound AMP other 2 in competition. Presence of AMP/ADP promotes phosphorylation and inhibits dephosphorylation of Thr172
  2. AMPK Related Kinases (ARKs) Highly conserved sequence at the site of the Thr172 Play roles in: cell polarity, cell proliferation (NUAKs), CREB related gene transcription.
  3. Knockdown of DTYMK in LKB1-WT and LKB1-mutant NSCLC cell lines. A, Western blot analyses of LKB1 expression in LKB1-WT (H358 and Calu-1) and LKB1-deficient (H2122 and A549) NSCLC cell lines. B, (shRNAs where used to knockdown DTYMK in LKB1 WT and LKB1-mutant cell lines. LKB1 mutant cell line show increased sensitivity to DTYMK knockdown)LKB1-WT (H358 and Calu-1) and LKB1-deficient (H2122 and A549) NSCLC cell lines were transduced with the indicated shRNAs for 1 day and then selected with 5 μg/mL puromycin (puro) for 2 days in six-well plates. The cells were collected by trypsin and replated into 96-well plates at 2,000 cells per well in 150 μL medium containing 5 μg/mL puromycin and measured daily using Promega's CellTiter-Glo Assay. The data represent mean ± SD for three replicates. C, the cells left from the replating were lysed for Western blot analysis of DTYMK expression. D, graph of dTDP levels in A549 cells transduced with the indicated shRNA for 4 days. The data represent mean ± SD for six replicates. Expression of DTYMK in these cells at the time of metabolite extraction was determined by Western blotting. E, LKB1-WT (H358 and Calu-1) and LKB1-deficient (H2122 and A549) NSCLC cell lines were plated into 96-well plates at 2,000 cells per well in 150 μL medium containing the indicated concentrations of AZD7762 or CHIR124 for 3 days. Viable cells were counted daily using Dojindo's Cell Counting Kit-8 Assay. The data represent mean ± SD for three repeats. Bottom: GI50 was calculated with GraphPad. (LKB1 Defficient cells are more sensitive to Chk1 inhibitors that LKB1 WT cells. Suggest more DNA damage in LKB1 mutated cells)
  4. The results show that both the cell lines (A549 LKB1 and A549 BABE) show a decrease in relative resazurin fluorescence at the highest concentration of the drug WZ4002. Only once the concentration of WZ4002 reaches 3 µM does the resazurin fluorescence begin to decrease. At lower concentrations than this WZ4002 has no obvious effect on the cells. AZD7762 has a more severe effect on the cells than WZ4002, as the proliferation of the cells is effectively decreased at concentrations as low as 0.03. At 0.3 µM AZD7762 cell growth is reduced by around 90%. At 10µM AZD6672 is extremely toxic to cell growth, the cells showing almost no proliferation at all. Both cell lines (A549 BABE and A549 LKB1) are effected to a similar extent by AZD7762. These results give us an indication of the concentrations of each drug at which we can expect to see drug response. We decided to run a PicoGreen assay treating cells with 0.1uM AZD and 3uM WZ.
  5. We used western blot to test both quantitatively and qualitatively for the presence of the proteins LKB1, the DNA damage response protein PARP, and for actin to use as a control. These proteins were probed for in both the A549 BABE and A549 LKB cells, either untreated, or treated with either the AZD7762 drug or the WZ40092 drug.
  6. From the western blot the abundance of each of the two proteins (PARP & LKB1) was calculated relative to the amount of actin. As expected LKB1 was not present in the BABE cells, but was present in the LKB1 cells. PARP was present at higher levels in the BABE cells, suggesting that the absense of LKB1 may be contributing to higher levels of DNA damage and therefore increased expression of the DNA damage response gene Parp.
  7. FACS analysis was used to investigate the cell cycle of the cells,
  8. Results from the PicoGreen assay of the A549 BABE cells. Control cells shown in blue. The results show that the addition of 0.1uMAZD does not have much of an affect on the cells. They display a slightly slower rate of proliferation between day 0 and day 1 however this is quickly overcome and the cells show a higher proliferation rate than the control cells. Addition of 3uM WZ however has a pronounced negative effect on the proliferation of the cells, displaying only roughly half the fluorescence intensity as the AZD treated cells on day 2.